Alpha-synuclein transgenic models
Test potential therapeutics for Parkinson’s disease and other synucleinopathies in mouse models with alpha-synuclein deposition and downstream pathological events
Alpha-synuclein (α-syn) inclusions are the main histopathological hallmark correlating with clinical symptoms of not only PD, but also other synucleinopathies such as dementia with Lewy bodies (DLB), and multiple systems atrophy (MSA).
Take advantage of InnoSer’s behavioural research expertise, flexibility, and collaborative approach for your research. Our in-house neurology experts have long-standing experience modelling PD in vivo using transgenic mouse lines and other neurodegenerative diseases. Our neurology experts help guide your decision on choosing the best model fit for your current research goals.
Transgenic alpha-synuclein models that InnoSer offers:
- Human α-syn models.
- A53T α-syn models (e.g. M83).
- Seeding in α-syn transgenic models.
Find the right model for you.
Compare our model capabilities and discover which of our neurology platforms suits your research needs
Test the efficacy of your treatments in the following battery of behavioural tests:
- Spontaneous Behavior (PhenoTyper)
- Neurological scoring
- Balance beam
- Grip strength
- Wire hanging
- Nest building
- MSD: Plasma, CSF and brain (α-syn, cytokines, NfL)
- (Digital) histopathology
- Immunohistochemistry (e.g. α-syn, neuroinflammation, neurodegeneration)
- Immunofluorescence and FISH
Related Parkinson’s Disease model options
MPTP Induced PD Models
Seeding Alpha-Synuclein Models
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
Need more information?
If you have any questions about how we can help accelerate your research,
then let us know